When Back Pain Turns Deadly: An Unusual Presentation of Lung Cancer

Publication date: Available online 28 January 2020Source: Respiratory Medicine Case ReportsAuthor(s): Melinda Vasser, Matthew KoroscilAbstractBack pain is a common presenting concern in physician offices and emergency departments alike, with etiologies ranging from minor injuries to severe life-threatening illnesses. This case details the clinical course of a 68-year-old former smoker with no pulmonary symptoms who presented with back pain multiple times before developing cord compression syndrome and being diagnosed with non-small cell lung cancer (NSCLC). It demonstrates the importance of lung cancer screening and the necessity of monitoring for red flags in cases of back pain.
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research

Related Links:

Abstract Back pain is a common presenting concern in physician offices and emergency departments alike, with etiologies ranging from minor injuries to severe life-threatening illnesses. This case details the clinical course of a 68-year-old former smoker with no pulmonary symptoms who presented with back pain multiple times before developing cord compression syndrome and being diagnosed with non-small cell lung cancer (NSCLC). It demonstrates the importance of lung cancer screening and the necessity of monitoring for red flags in cases of back pain. PMID: 32025486 [PubMed]
Source: Respiratory Care - Category: Respiratory Medicine Authors: Tags: Respir Med Case Rep Source Type: research
Anlotinib is an anti ‐angiogenic drug that targets vascular endothelial growth factor receptor, platelet‐derived growth factor receptor, fibroblast growth factor receptor, c‐Kit, and other kinases and has been approved for the treatment of advanced non‐small cell lung cancer (NSCLC). As in other small‐molecule tyrosine kinase inhibitors, adverse effects such as hypertension and cardiotoxicity may be seen. However, the relationship between anlotinib and aortic dissection has not been previously reported. Here, we present a case of aortic dissection in a 58‐year‐old male patient with advanced NSCLC wit hout his...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Conclusions The recent, first randomized clinical trial demonstrated overall and progression free survival benefits after SBRT to oligometastatic disease which supports prior retrospective case series (6). The spine is a common site of metastatic bone disease, and as high quality data continue to mature, along with completion of additional randomized clinical trials, it is expected that utility of SBRT to the spine will increase in the future. Spine SBRT is unique due to the requirement of sharp dose falloff to prevent serious neurologic morbidity. With recent advances in radiotherapy planning, robotic patient positionin...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We report a case of a 60-year-old female, suffering from non-small cell lung cancer (NSCLC), with refractory lower back pain, as expression of malignant psoas syndrome (MPS). MPS is a rare and difficult-to-treat cancer-pain syndrome, unresponsive to majority of analgesic therapy, related to psoas muscle metastasis; it is usually caused by different tumors such as uterus, ovary, bladder, prostate, colon-rectum, lymphoma, melanoma and sarcoma and represents an uncommon finding in NSCLC patients. PMID: 30968671 [PubMed - in process]
Source: Monaldi Archives for Chest Disease - Category: Respiratory Medicine Tags: Monaldi Arch Chest Dis Source Type: research
Conclusion The expression of the components of the PTN-MK-RPTPβ/ζ axis in immune cells and in inflammatory diseases suggests important roles for this axis in inflammation. Pleiotrophin has been recently identified as a limiting factor of metainflammation, a chronic pathological state that contributes to neuroinflammation and neurodegeneration. Pleiotrophin also seems to potentiate acute neuroinflammation independently of the inflammatory stimulus while MK seems to play different -even opposite- roles in acute neuroinflammation depending on the stimulus. Which are the functions of MK and PTN in chronic neuroinfla...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Lung cancer is the leading cause of cancer-related death worldwide [1], and bone metastases occur in 20-30 % of patients with lung cancer [2]. Bone metastases result in several unfavorable skeletal-related events (SREs), including bone pain, pathological fractures, spinal cord compression, hypercalcemia, and the need for bone radiation. SREs have a negative effect on the quality of life (QOL) of cancer patients [3]. Zoledronate (ZOL), a nitrogen-containing bisphosphonate (N-BP), has been shown to reduce the incidence of SREs in cancer patients with bone metastases, including lung cancer [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
From portable genome sequencers until genetic tests revealing distant relations with Thomas Jefferson, genomics represents a fascinatingly innovative area of healthcare. As the price of genome sequencing has been in free fall for years, the start-up scene is bursting from transformative power. Let’s look at some of the most amazing ventures in genomics! The amazing journey of genome sequencing Genome sequencing has been on an amazing scientific as well as economic journey for the last three decades. The Human Genome Project began in 1990 with the aim of mapping the whole structure of the human genome and sequencing ...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Genomics Personalized Medicine AI artificial intelligence bioinformatics cancer DNA dna testing DTC gc3 genetic disorders genetics genome sequencing personal genomics precision medicine Source Type: blogs
Conclusions:Efficacy and safety outcomes for the ‘true ESL monotherapy’ patient subgroup (no AEDs added back during the OLE) were favorable and generally consistent with those for the total OLE population, although with fewer SAEs and discontinuations due to TEAEs.Study Supported by: Sunovion Pharmaceuticals Inc.Disclosure: Dr. Chung has received personal compensation for activities with UCB Pharma, Eisai, Lundbeck, Upsher-Smith, and Sunovion. Dr. Chung has received research support from Lundbeck, UCB Pharma, Upsher-Smith, and SK Life Sciences. Dr. Sinha has received personal compensation for activities with Mo...
Source: Neurology - Category: Neurology Authors: Tags: Epilepsy and Clinical Neurophysiology: Therapeutics I Source Type: research
Conclusions:While the vertebral body infarct sign is often recognized by neuro-radiologists, it is still relatively unknown to practicing neurologists. Early recognition of spinal cord infarct allows for timely evaluation for precipitating factors and initiation of secondary preventative therapies to decrease risk of further vascular events.Disclosure: Dr. Chan has nothing to disclose. Dr. Chan has nothing to disclose. Dr. Farooque has nothing to disclose. Dr. Nowak has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Tags: Cerebrovascular Disease Case Reports II Source Type: research
By Stacy SimonThe US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) to treat people with head and neck squamous cell carcinoma that has spread or come back after previous chemotherapy treatment. It’s the first immunotherapy drug approved for head and neck cancer. Keytruda is already approved for melanoma and non-small cell lung cancer.The FDA based its approval on a clinical trial of 174 people with head and neck squamous cell carcinoma that had spread or come back after they were treated with platinum-based chemotherapy. Tumors shrank or disappeared in 16% of the participants who were given...
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Oral Cavity and Oropharyngeal Cancer Source Type: news
More News: Back Pain | Cancer | Cancer & Oncology | Emergency Medicine | Lung Cancer | Non-Small Cell Lung Cancer | Pain | Respiratory Medicine | Smokers